CKD Drug Development Summit

Meet Novalix at the 8th Annual CKD (Chronic Kidney Disease) Drug Development Summit in Boston, MA.

This event brings together leading experts to tackle urgent unmet needs across rare and common renal conditions, from ADPKD and IgA nephropathy to cardiorenal syndromes and transplant complications. With 44+ renowned speakers and a program spanning discovery to commercialization, attendees will gain actionable insights on target identification, adaptive trial design, regulatory strategies, and integrating the patient voice throughout development.

PCKD, the most relevant model for ADPKD

We are delighted to share that Daniel Comas, PhD, Director Translational Pharmacology, in vivo pharmacology, biomarkers & histology, will contribute to the scientific program with a poster presentation on our PCKD model.

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder, affecting 12 million people globally. It is characterized by the development of fluid-filled kidney cysts, which often leads to kidney failure. The vasopressin receptor 2 antagonist, Tolvaptan, is the only approved treatment that slows the progression of ADPKD. Nevertheless, there is still a high unmet need for treatment options for patients with ADPKD because Tolvaptan has limited efficacy and non-negligible side effects.

Don’t miss the poster presentation and discover how and why PCKD is the most relevant pre-clinical model for human ADPKD.

Looking for support for your CKD projects? Contact our Daniel and Tim experts to discuss your development programs. We look forward to meeting you there!

Discover more on our kidney disease models here.